SGMT · Sagimet Biosciences Inc.
$8.93
-0.10 (-1.11%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$574.35M
Shares
62.16M
Volume · Oct 5
1.53M
Avg daily vol (3M)
1.24M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.03
Open$9.08
Day$8.40–9.12
52W close$4.55–11.17
Avg vol 30d1.3M
Short int10.3M · 16.5% float · 10.6d
Short vol64%
Last earningsMay 12, 2026
DataJul 2023–Oct 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Mar 26, 2027
Est · unconfirmed
· in 24 wks
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+23.9%
Trailing year
Short interest
16.5%
Latest settlement · 10.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+26%
above
Price vs 50-day avg
−8%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
68%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−17%
trailing
6-month return
+63%
trailing
YTD return
+53%
this year
Relative strength
+51%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+40% holders QoQ · +58 funds added
Insider flow
Distributing
Net -$578.9K over 90 days · 100% sells
Short interest
Rising
16.51% of float · ▲ +1.5% MoM · 10.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
123 holders — near 3-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−50%
past year
ATR
8.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+26%
Bullish
Price vs 50-day avg
−8%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
68%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $10 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+40% holders QoQ · +58 funds added
Insider flow
Distributing
Net -$578.9K over 90 days · 100% sells
Short interest
Rising
16.51% of float · ▲ +1.5% MoM · 10.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
123 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $9 · 68%
Range high $11
vs 200-day avg +26%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SGMT
this stock
Sagimet Biosciences Inc.
|
$574.35M | +52.5% | — | — | 16.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SGMT | -9.2% | -17.5% | +63.0% | -8.6% | +52.5% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -10.4% | -18.1% | +51.4% | -10.2% | +38.9% |